Helen L. Wu

Helen L. Wu

Auto-generated profile, based on publicly available information

Helen L. Wu

Oregon National Primate Research Center and Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97007, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
GWGabriela M Webb
Gabriela M Webb
JMJhomary Molden
Jhomary Molden
KBKathleen Busman-Sahay
Kathleen Busman-Sahay
SAShaheed Abdulhaqq
Shaheed Abdulhaqq
HWHelen L Wu
Helen L Wu
JSJonah B Sacha
Jonah B Sacha
Despite the success of antiretroviral therapy (ART) to halt viral replication and slow disease progression, this treatment is not curative and there remains an urgent need to develop approaches to clear the latent HIV reservoir. The human IL-15 superagonist N-803 (formerly ALT-803) is a promising anti-cancer biologic with potent immunostimulatory properties that has been extended into the field of HIV as a potential “shock and kill” therapeutic for HIV cure. However, the ability of N-803 to reactivate latent virus and modulate anti-viral immunity in vivo under the cover of ART remains undefined. Here, we show that in ART-suppressed, simian-human immunodeficiency virus (SHIV)SF162P3-infected rhesus macaques, subcutaneous administration of N-803 activates and mobilizes both NK cells and SHIV-specific CD8+ T cells from the peripheral blood to lymph node B cell follicles, a sanctuary site for latent virus that normally excludes such effector cells. We observed minimal activation of memory CD4+ T cells and no increase in viral RNA content in lymph node resident CD4+ T cells post N-803 administration. Accordingly, we found no difference in the number or magnitude of plasma viremia timepoints between treated and untreated animals during the N-803 administration period, and no difference in the size of the viral DNA cell-associated reservoir post N-803 treatment. These results substantiate N-803 as a potent immunotherapeutic candidate capable of activating and directing effector CD8+ T and NK cells to the B cell follicle during full ART suppression, and suggest N-803 must be paired with a bona fide latency reversing agent in vivo to facilitate immune-mediated modulation of the latent viral reservoir. IL-15 regulates NK and memory T cell homeostasis and is therefore being explored for clinical immunotherapy of chronic diseases like cancer and HIV. To explore the applicability of the clinical grade IL-15 superagonist N-803 to HIV cure strategies we tested the impact of N-803 on host immunity and latent virus in SHIV-infected rhesus macaques. Our results suggest that N-803 beneficially modulates effector NK and CD8+ T cells by expanding the numbers of these cells and redistributing them to lymph node B cell follicles, a site known to harbor persistent latent virus during ART. However, our results further suggest that N-803 does not perturb the viral reservoir present in memory CD4+ T cells and that in order to fully unlock the immunotherapeutic potential of N-803 it must be paired with latency reversal agents.

25 May 2023 in Immunity
Verified
Journal Article
Closed access
HWHelen L. Wu
Helen L. Wu
KBKathleen Busman-Sahay
Kathleen Busman-Sahay
WWWhitney C. Weber
Whitney C. Weber
CWCourtney M. Waytashek
Courtney M. Waytashek
CBCarla D. Boyle
Carla D. Boyle
JSJonah B. Sacha
Jonah B. Sacha

15 April 2020 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
Benjamin BurwitzBenjamin Burwitz
Benjamin Burwitz
PHPatrick K. Hashiguchi
Patrick K. Hashiguchi
MMMandana Mansouri
Mandana Mansouri
CMChristine Meyer
Christine Meyer
RGRoxanne M. Gilbride
Roxanne M. Gilbride
JSJonah B. Sacha
Jonah B. Sacha
Currently 247 million people are living with chronic hepatitis B virus infection (CHB), and the development of novel curative treatments is urgently needed. Immunotherapy is an attractive approach to treat CHB, yet therapeutic approaches to augment the endogenous hepatitis B virus (HBV)–specific T cell response in CHB patients have demonstrated little success. In this study, we show that strain 68-1 rhesus macaque (RM) CMV vaccine vectors expressing HBV Ags engender HBV-specific CD8+ T cells unconventionally restricted by MHC class II and the nonclassical MHC-E molecule in RM. Surface staining of human donor and RM primary hepatocytes (PH) ex vivo revealed the majority of PH expressed MHC-E but not MHC class II. HBV-specific, MHC-E–restricted CD8+ T cells from RM vaccinated with RM CMV vaccine vectors expressing HBV Ags recognized HBV-infected PH from both human donor and RM. These results provide proof-of-concept that MHC-E–restricted CD8+ T cells could be harnessed for the treatment of CHB, either through therapeutic vaccination or adoptive immunotherapy. Key Points RhCMV/HBV vectors engender MHC-E–restricted CD8+ T cell responses in RM. HD and RM PH express MHC-E. PH present HBV Ag to MHC-E–restricted CD8+ T cells from RhCMV/HBV-inoculated RM.

7 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
XCXiao L. Chang
Xiao L. Chang
GWGabriela M. Webb
Gabriela M. Webb
HWHelen L. Wu
Helen L. Wu
JGJustin M. Greene
Justin M. Greene
SAShaheed Abdulhaqq
Shaheed Abdulhaqq
JSJonah B. Sacha
Jonah B. Sacha
In the absence of a prophylactic vaccine, the use of antiretroviral therapy (ART) as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition by uninfected individuals is a promising approach to slowing the epidemic, but its efficacy is hampered by incomplete patient adherence and ART-resistant variants. Here, we report that competitive inhibition of HIV Env-CCR5 binding via the CCR5-specific antibody Leronlimab protects rhesus macaques against infection following repeated intrarectal challenges of CCR5-tropic SHIVSF162P3. Injection of Leronlimab weekly at 10 mg/kg provides significant but partial protection, while biweekly 50 mg/kg provides complete protection from SHIV acquisition. Tissue biopsies from protected macaques post challenge show complete CCR5 receptor occupancy and an absence of viral nucleic acids. After Leronlimab washout, protected macaques remain aviremic, and adoptive transfer of hematologic cells into naïve macaques does not transmit viral infection. These data identify CCR5 blockade with Leronlimab as a promising approach to HIV prophylaxis and support initiation of clinical trials.

13 January 2020 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
HWHelen L. Wu
Helen L. Wu
WWWhitney C. Weber
Whitney C. Weber
CSChristine Shriver‐Munsch
Christine Shriver‐Munsch
TSTonya Swanson
Tonya Swanson
MNMina Northrup
Mina Northrup
JSJonah B. Sacha
Jonah B. Sacha

22 November 2021 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
SAShaheed Abdulhaqq
Shaheed Abdulhaqq
AVAbigail B. Ventura
Abigail B. Ventura
JRJason S. Reed
Jason S. Reed
ABArman A Bashirova
Arman A Bashirova
KBKatherine B. Bateman
Katherine B. Bateman
BBBenjamin N. Bimber
Benjamin N. Bimber
CD8+ T cells are key mediators of antiviral and antitumor immunity. The isolation and study of Ag-specific CD8+ T cells, as well as mapping of their MHC restriction, has practical importance to the study of disease and the development of therapeutics. Unfortunately, most experimental approaches are cumbersome, owing to the highly variable and donor-specific nature of MHC-bound peptide/TCR interactions. Here we present a novel system for rapid identification and characterization of Ag-specific CD8+ T cells, particularly well suited for samples with limited primary cells. Cells are stimulated ex vivo with Ag of interest, followed by live cell sorting based on surface-trapped TNF-α. We take advantage of major advances in single-cell sequencing to generate full-length sequence data from the paired TCR α- and β-chains from these Ag-specific cells. The paired TCR chains are cloned into retroviral vectors and used to transduce donor CD8+ T cells. These TCR transductants provide a virtually unlimited experimental reagent, which can be used for further characterization, such as minimal epitope mapping or identification of MHC restriction, without depleting primary cells. We validated this system using CMV-specific CD8+ T cells from rhesus macaques, characterizing an immunodominant Mamu-A1*002:01-restricted epitope. We further demonstrated the utility of this system by mapping a novel HLA-A*68:02-restricted HIV Gag epitope from an HIV-infected donor. Collectively, these data validate a new strategy to rapidly identify novel Ags and characterize Ag-specific CD8+ T cells, with applications ranging from the study of infectious disease to immunotherapeutics and precision medicine.